InvestorsHub Logo
Followers 37
Posts 2736
Boards Moderated 0
Alias Born 04/22/2019

Re: None

Wednesday, 08/16/2023 10:07:10 PM

Wednesday, August 16, 2023 10:07:10 PM

Post# of 64926
$TSOI The battle between RESTEM LLC and JADICELL LLC has taken a new twist, with Tim Dixon, the CEO of TSOI, stepping into the spotlight. His amicus brief is like a cannonball of truth, crashing into the courtroom and revealing the alleged lies and deception perpetrated by both parties. It's like a courtroom bombshell that's sending shockwaves through biotech Cos in Sandiego and all over the world.
The lower court's verdict, squashing all claims on IPR made by RESTEM LLC and favoring JADICELL LLC, seems to have set the stage. And now, in this appellate court, the amicus brief by Tim Dixon is a daring move, calling out the collusion between the two parties and suggesting their attempts to stall TSOI's ongoing Phase 3 clinical trial for lung regeneration.

Let's not forget the tangled licensing agreement involving JADICELL LLC and TSOI. It's like a legal labyrinth that has led to accusations of non-compliance and a murky situation with the Mother CELL LOT.

As the appellate court judge considers this intricate puzzle of claims and counterclaims, one can't help but wonder: Will the judge refer the matter to the Department of Justice if they suspect foul play? Or will the evidence presented by TSOI's CEO, Tim Dixon, sway the judgment in a different direction?

Either way, it seems that TSOI could stand to benefit from the actions taken in the appellate court. With the spotlight now on the alleged perjury and collusion, the truth could be on the verge of unveiling itself, reshaping the course of this legal saga. 🕵️‍♂️📜🔍
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TSOI News